SCINTIMUN
LIVE

Serial Number

79429309

Owner

Telix Pharmaceuticals Limited

Attorney

Andrew S. Ehard

Filing Date

Mar 14, 2025

Add to watchlist:

No watchlists yet
View on USPTO

SCINTIMUN Trademark

Serial Number: 79429309

SCINTIMUN is a trademark filed by Telix Pharmaceuticals Limited on March 14, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

Telix Pharmaceuticals Limited (38 trademarks)

Suite 401, 55 Flemington Road

Entity Type: 99

Trademark Details

Filing Date

March 14, 2025

Registration Date

Not Registered

Published for Opposition

June 16, 2026

Goods & Services

Medical apparatus, namely, infusion and injection devices for administering drugs and diagnostic radiopharmaceuticals; apparatus for medical purposes in the nature of drug delivery devices sold empty, namely, syringes and infusion sets for diagnostic radiopharmaceuticals; medical devices for treating cancer; diagnostic imaging apparatus for medical use being medical imaging apparatus for diagnosing medical conditions

Chemical preparations for pharmaceutical purposes, namely, diagnostic radiopharmaceutical preparations; pharmaceutical preparations for the imaging, diagnosing and monitoring of cancer, namely, contrast media for use with imaging medical equipment, diagnostic reagents and contrast media for medical use, diagnostic radiopharmaceutical preparations, and radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 16, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jun 16, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 10, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 19, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 19, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
May 19, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
May 19, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 19, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 30, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 30, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 30, 2026 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jan 22, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 1, 2026 NREP
REFUSAL PROCESSED BY IB
Nov 30, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 9, 2025 RFCS
REFUSAL PROCESSED BY MPU
Nov 9, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 19, 2025 RFCR
NON-FINAL ACTION WRITTEN
Sep 18, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 15, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 15, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 13, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 7, 2025 REPR